Flow Cytometry of Hematological Malignancies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: 1 December 2024 | Viewed by 1125
Special Issue Editors
Interests: flow cytometry; hematopathology (leukemias and lymphomas)
Special Issue Information
Dear Colleagues,
Flow cytometry (FC) is a primary tool for establishing immunophenotypes of cell populations to identify and characterize hematolymphoid disorders. Its analytic approach is evolving to facilitate efficient and accurate analysis in a world with ever-changing challenges and opportunities created by novel therapeutic approaches and technological advancements.
In this Special Issue, we will present current FC diagnostic approaches to various hematologic malignancies (including lymphoblastic leukemia, lymphoma, plasma cell neoplasm, and acute myeloid leukemia) and strategies used in minimal/measurable residual disease analysis and post-immunotherapy settings [including chimeric antigen receptor-T cell therapy (CAR-T) and bispecific T-cell engager (BiTE) monoclonal antibodies]. Lastly, future directions of the field will be examined, including the incorporation of spectral flow cytometry into clinical practice and the increased use of machine learning for flow cytometry analysis.
Prof. Dr. Weina Chen
Prof. Dr. Franklin S. Fuda
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- flow cytometry
- minimal or measurable residual disease (MRD)
- immunotherapy
- leukemia
- lymphoma
- myeloma
- chimeric antigen receptor T cells (CAR-T)
- bispecific T-cell engager (BiTE)
- B-cell maturation antibody (BCMA)
- spectral flow cytometry
- machine learning
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
